This trial is evaluating whether Benralizumab will improve 1 primary outcome, 13 secondary outcomes, and 2 other outcomes in patients with Bronchiectasis. Measurement will happen over the course of During first 52 weeks.
This trial requires 420 total participants across 2 different treatment groups
This trial involves 2 different treatments. Benralizumab is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"There is currently no cure for bronchiectasis or a cure that will provide dramatic improvement in quality of life. Treating exacerbating disease features in any manner, including bronchiectasis, is the standard of care. Patients should be encouraged to exercise to make their symptoms subside." - Anonymous Online Contributor
"Bronchiectasis is a chronic lung disease caused by persistent infections of the airways, secondary to a malfunction or insufficiency of the airway clearance (i.e. mucociliary clearance). In healthy people, mucociliary clearance clears 99.9% of airway surface liquid in 8 hours. This is impaired in bronchiectasis, decreasing the effectiveness of the airway lining membrane to act as a filter for inhaled airborne substances. Bacterial infections are the main cause of bronchiectasis. The chronic cough is a hallmark of bronchiectasis. The underlying disease can be either a congenital or acquired defect." - Anonymous Online Contributor
"The main signs of bronchiectasis included night-time dyspnoea, and a decrease in the pulse rate during the day. All suspected patients should report their symptoms back to their doctor." - Anonymous Online Contributor
"In this series of patients presenting with bronchiectasis, the most common causes were chronic upper or lower airway obstruction. Bronchiectasis also occurred in conjunction with other health problems." - Anonymous Online Contributor
"Around 14.5 million people in the United States have bronchial bronchiectasis. These diseases will represent over a quarter of people who die under 50. We can do more for these patients than just diagnose them." - Anonymous Online Contributor
"Most patients with bronchiectasis are taking inhaled corticosteroid, such as beclomethasone dipropionate. Inhalers combined with low dose triple therapy can be useful. Inhalers should be used after 6 months of inhaled steroid therapy." - Anonymous Online Contributor
"Benralizumab has an acceptable safety profile overall and can be safely administered to patients with idiopathic pulmonary fibrosis in the context of an ongoing clinical trial. Further safety data such as information on its effect on infections are awaited." - Anonymous Online Contributor
"Patients with chronic bronchiectasis in whom IFN-alpha-2a or IFN-b was ineffective demonstrated significantly greater improvements in dyspnea when treated with benralizumab. Findings from a recent study are consistent with clinical and preclinical data suggesting that IL-5 inhibitors may potentially benefit patients with chronic obstructive pulmonary disease." - Anonymous Online Contributor
"The findings of this study have important implications for the treatment and care of patients with bronchiectasis. Although bronchiectasis treatment options are limited, clinical trial information should be given to patients to enable informed decision-making." - Anonymous Online Contributor
"Bronchiectasis is a very common disease in Latin America and Europe, affecting 3 or 4 million people at any time. In the United States, it occurs about 1 in 750 people, but almost 400 (0.3%) will die. Bronchiectasis can have debilitating effects on daily activity because of shortness of breath, coughing up blood and weight loss. Treatment involves pulmonary rehabilitation. Patients should be identified and screened for the disease, with special attention to lung damage (e.g., pulmonary tuberculosis and COPD). Many of those with bronchiectasis are suffering from debilitating airway obstruction caused by abnormal narrowing of the airways, known as "airway destruction" - this can cause chronic coughing and loss of vital lung function." - Anonymous Online Contributor
"The short-term beneficial effect of benralizumab on sputum-producing cells and lung function did not reach a statistical significance by end of week 4, but there was a trend toward a positive effect in those who received the drug. The drug appeared to be more clinically beneficial compared to placebo at 1 month." - Anonymous Online Contributor
"The combination of oral antibiotics and an IM MDA with BZ or BZ+RT was found to have a higher cure rate than BZ alone. Benralizumab should be given in combination with antibiotics, such as a cethromycin, but not with corticosteroids." - Anonymous Online Contributor